The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's Prime Minister ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...
Columbus joins the states of Arkansas, California, Kansas, Kentucky, Minnesota and Mississippi and other cities and counties ...
The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...
LONDON: Doctors worldwide should diagnose obesity differently, relying on broader criteria and taking into account when the condition causes ill-health, according to a new framework drawn up by ...
Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.
(Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired ...